NASDAQ · FOSLHealthcareMedical Instruments & Devices

Fossil Group financials

$6.16+2.33%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

QuarterQ2 '26
Jul 4
Q1 '26
Apr 4
Q4 '25
Jan 3
Q3 '25
Oct 4
Q2 '25
Jul 5
Q1 '25
Apr 5
Q4 '24
Dec 28
Q3 '24
Sep 28
Q2 '24
Jun 29
Q1 '24
Mar 30
Q4 '23
Dec 30
Q3 '23
Sep 30
Revenue$209.7M$224.8M$280.5M$270.2M$220.4M$233.3M$342.3M$287.8M$260.0M$254.9M$421.3M$344.1M
Gross profit$130.8M$134.7M$161.0M$132.4M$126.7M$143.0M$184.6M$142.2M$136.9M$133.5M$200.5M$161.7M
Gross margin62.4%59.9%57.4%49.0%57.5%61.3%53.9%49.4%52.6%52.4%47.6%47.0%
Operating income$3.2M$12.0M$860.0K-$21.7M$8.5M-$6.7M-$16.3M-$24.5M-$34.0M-$29.2M-$24.0M-$46.4M
Net income-$10.6M-$810.0K-$18.6M-$39.9M-$2.3M-$17.6M-$7.6M-$32.0M-$38.8M-$24.3M-$28.2M-$61.1M
Net margin−5.1%−0.4%−6.6%−14.8%−1.0%−7.5%−2.2%−11.1%−14.9%−9.5%−6.7%−17.7%
Diluted EPS$-0.18$-0.01$-0.33$-0.76$-0.04$-0.33$-0.14$-0.60$-0.73$-0.46$-0.54$-1.16
EBITDA$10.3M$15.9M$15.9M-$11.1M$18.8M$12.6M$16.3M-$14.8M-$12.8M-$14.3M-$7.1M-$25.2M
Operating cash flow-$9.2M-$21.8M$15.2M-$22.2M$9.4M-$60.4M$30.5M-$22.8M$38.4M$622.0K$48.5M-$24.9M
Free cash flow-$10.1M-$22.7M$14.1M-$22.5M$8.6M-$60.6M$28.5M-$24.1M$36.6M-$1.1M$47.1M-$27.5M
Diluted shares59.0M58.4M57.1M52.4M53.6M53.3M53.2M53.2M52.9M52.5M52.5M52.5M

Balance sheet

Period endJul 4Apr 4Jan 3Oct 4Jul 5Apr 5
Cash & equivalents$79.0M$81.4M$95.8M$79.2M$109.9M$78.3M
Short-term investments$0.00$0.00$0.00$0.00$0.00$0.00
Total debt$203.0M$195.3M$177.8M$176.0M$179.0M$179.5M
Total assets$653.1M$654.5M$689.3M$701.0M$704.5M$686.0M
Total liabilities$579.1M$571.4M$602.5M$604.9M$570.6M$561.6M
Shareholders' equity$74.0M$83.2M$86.8M$96.1M$133.9M$124.4M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology